Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by Indomitableon Jul 24, 2016 12:45am
67 Views
Post# 25079306

RE:RE:Positivity vs rollback

RE:RE:Positivity vs rollbackI think you are using the wrong charts to get your calculations. Use google finance to get accurate prices where splits are occuring at some point on the chart. Stockhouse charts and other sites for some reason don't take splits into account when they do their charts so you get inaccurate historical stock prices.

I hope you all know what I mean. 

To see what I mean, compare stock chart prices of a stock that has a split somewhere in its history using google finance charts and then check the exact same stock out using stockhouse charts. Simple as that and you will see what I mean.

I checked out those companies you have listed and some growth in share price percentage is double or more than what your numbers are since the split and some numbers are less. Regardless you do make a good point by giving examples that just because shares consolidate does not mean that the share price is going to take some nasty dive because of it.

The share price should be based off of what the market values it at, and ultimately the true book value is supposed catch up to the market value over points in time. There are tonnes of companies out their, especially research and develpment companies whose market value is worth ten times if not 100,000 times what its current book value is. This would be the case especially with research and development companies who can have market caps in the millions or even over a billion during the ten or more years they exist where they are doing nothing but phase 1,2,3 tirals and dont even have a product out on the market.

Investors not only look at true book value, but also look at future potential value when considering what they think a share is worth. Look at nemaska and its 300 million market cap right now and they have yet to put one shovel in the ground or start work on even their mini factory.

Go by your own dd, not speculation. Stick to the facts not fiction.
it's weekend time! emoticon
Indomitable Cool





Bullboard Posts